• +1-646-491-9876
    • +91-20-67278686

    Search

    Urinary Incontinence - Pipeline Review, H1 2017

    Urinary Incontinence - Pipeline Review, H1 2017

    • Report Code ID: RW0001689419
    • Category Healthcare
    • No. of Pages 66
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Urinary Incontinence - Pipeline Review, H1 2017, provides an overview of the Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline landscape.

    Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder’s contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes and other skin disorders. Risk factors include age, gender, overweight, smoking and other kidney diseases. Treatment includes anticholinergics and topical estrogen.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Urinary Incontinence - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

    Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Urinary Incontinence (Genito Urinary System And Sex Hormones).
    - The pipeline guide reviews pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Urinary Incontinence - Overview
    Urinary Incontinence - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Urinary Incontinence - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Urinary Incontinence - Companies Involved in Therapeutics Development
    Astellas Pharma Inc
    Celogos SA
    Cook MyoSite Inc
    FemmePharma Global Healthcare Inc
    GTx Inc
    Innovacell Biotechnologie AG
    Ipsen SA
    Outpost Medicine Ltd
    Pfizer Inc
    Taiho Pharmaceutical Co Ltd
    Takeda Pharmaceutical Company Ltd
    Urinary Incontinence - Drug Profiles
    (mirabegron + solifenacin succinate) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    abobotulinumtoxina - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cell Therapy for Ischemic Heart Failure, Gastrointestinal Disorders and Urological Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cell Therapy for Urinary Incontinence - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    enobosarm - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gtx-027 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ICES-13 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OP-233 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    oxybutynin chloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Prof-003 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RCD-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Agonize 5-HT2C for Urinary Incontinence - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit NET for Stress Urinary Incontinence - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TAS-303 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Urinary Incontinence - Dormant Projects
    Urinary Incontinence - Discontinued Products
    Urinary Incontinence - Product Development Milestones
    Featured News & Press Releases
    Jul 18, 2016: BioLife Solutions Products Embedded in Cook MyoSite Phase 3 Cell Therapy Clinical Trial for Stress Urinary Incontinence
    Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-024 (enobosarm) on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting
    Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-027 on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting
    Jan 13, 2016: GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence
    Oct 13, 2015: GTx Receives FDA Clearance to Initiate Clinical Trial in Stress Urinary Incontinence
    May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial
    Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg
    Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference
    Dec 05, 2011: Pfizer’s Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients
    Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency
    Aug 30, 2011: Innovacell passes a further milestone
    Feb 22, 2011: Innovacell makes further progress on product development
    Jun 15, 2010: Innovacell Enrolls First Patient In Phase IIb Study Of Urocell For Treatment Of Urinary Incontinence
    Oct 31, 2008: Fesoterodine Approved in the U.S
    Feb 28, 2007: HRA Pharma Invest An Additional Euro 2.5 M In Cell Therapy Through Its Subsidiary Celogos
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Urinary Incontinence, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Urinary Incontinence - Pipeline by Astellas Pharma Inc, H1 2017
    Urinary Incontinence - Pipeline by Celogos SA, H1 2017
    Urinary Incontinence - Pipeline by Cook MyoSite Inc, H1 2017
    Urinary Incontinence - Pipeline by FemmePharma Global Healthcare Inc, H1 2017
    Urinary Incontinence - Pipeline by GTx Inc, H1 2017
    Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, H1 2017
    Urinary Incontinence - Pipeline by Ipsen SA, H1 2017
    Urinary Incontinence - Pipeline by Outpost Medicine Ltd, H1 2017
    Urinary Incontinence - Pipeline by Pfizer Inc, H1 2017
    Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
    Urinary Incontinence - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Urinary Incontinence - Dormant Projects, H1 2017
    Urinary Incontinence - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Urinary Incontinence - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Urinary Incontinence, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Astellas Pharma Inc
    Celogos SA
    Cook MyoSite Inc
    FemmePharma Global Healthcare Inc
    GTx Inc
    Innovacell Biotechnologie AG
    Ipsen SA
    Outpost Medicine Ltd
    Pfizer Inc
    Taiho Pharmaceutical Co Ltd
    Takeda Pharmaceutical Company Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//urinary-incontinence-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//urinary-incontinence-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//urinary-incontinence-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments